MSCs modified with the angiotensin-converting enzyme (ACE) 2 gene could significantly inhibit renin-angiotensin system (RAS) activation and reduce glomerular fibrosis [81], yet research literature on treating DN is still limited. This evidence concerns the gene REN and liver dysplastic nodule.